Market Overview

UPDATE: Jefferies Raises PT on Merck & Co. Following Global Pharma Review

Share:
Related MRK
FDA Approves Pediatric Indication for EMEND® (aprepitant) Capsules in Combination with Other Antiemetic Agents
Organovo CEO Keith Murphy: 'People Are Missing The Forest For The Trees'
How Do Top 10 Healthcare Dogs Get 9.14% More Net Gains From 5 Lowest Priced By September 2016? (Seeking Alpha)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Merck & Co. (NYSE: MRK), and raised the price target from $54.00 to $56.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Merck & Co. closed on Thursday at $48.73.

Latest Ratings for MRK

DateFirmActionFromTo
Aug 2015JefferiesMaintainsHold
Aug 2015BMO CapitalUpgradesMarket PerformOutperform
Jun 2015Piper JaffrayInitiates Coverage onNeutral

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (MRK)

View Comments and Join the Discussion!

Get Benzinga's Newsletters